- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00713947
Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control (Aspylori)
April 20, 2015 updated by: Assistance Publique - Hôpitaux de Paris
Comparative Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control on the Gastric Lesions Induced by the Aspirin With the Low Dose Among Patients Treated With the Long Course
Low dose of aspirin is the main cause of gastro-duodenal ulcer.
The best prevention is not definite particularly in patients without history of ulcer and infected by H. pylori.The aim of the study is to evaluate the gastric damage induced by aspirin in patients with H. pylori infection but who have any history of ulcer.
Study Overview
Status
Withdrawn
Intervention / Treatment
Detailed Description
The aim of the study is to compare the protective effect of H. pylori eradication versus Pantoprazole versus placebo on the gastric damage induced by low dose of aspirin.
Treatment are attributed by randomisation.
Patients are followed for 6 months and gastric damage are evaluated by endoscopy at the end of this period.
Study Type
Interventional
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Paris, France, 75181
- Hotel Dieu Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients of more than 18 years old
- Coronarography or coronary imaging or supra-aortic arterial trunks ultrasound examination performed since less 7 months and having at least an arterial vascular stenosis
- Indication for aspirin treatment for at least 12 months (at the moment of the visit of inclusion) at a posology from 80 to 125 mg per day. The treatment must be prescribed since less than 7 months.
- Patient who had since less 7 month a positive Helicobacter Pylori serology.
- For the women in age to procreate, effective mode of contraception (oral contraception, surgical sterilization, coil)
- Patient having given an informed consent according to recommendation of the CPP (institutional ethical committee).
Exclusion Criteria:
- treatment by anti-coagulant, whatever its nature and its posology, by proton pump inhibitor, H2 receptor antagonists or antiacid having to be continued beyond the day of inclusion
- Treatment by methotrexate in progress or stopped since less 3 months.
- Time of more 7 months enters the beginning of the treatment by aspirin and the visit of inclusion
- Treatment by NSAID (even occasional or self medication) under or stopped since less 3 months.
- Treatment by anti-platelet drug (clopidogrel, ticlopidine, flurbiprofen, dipyridamole or antagonist of receptor GPIIb/IIIa) in progress or stopped since less than 10 days.
- Patient with a serious pathology compromising survival in the 6 month to come.
- Patient with renal or respiratory insufficiency or a hepatic pathology having a clinical repercussion.
- History of surgery of esophagus, stomach or duodenum.
- History of digestive tract bleeding or gastro-duodenal ulcer or esophagal ulcerating proven by endoscopy.
- Allergy known to clarithromycin.
- Psychiatric disorder not controlled by treatment.
- Patients all ready include in a therapeutic protocol or to be followed for 6 month.
- Alcohol consumption higher than 100gr. per day.
- Patient non suitable for participating in the protocol or to be followed for 6 month.
- History of intolerance to salicylate.
- Constitutional or acquired hemorrhagic disease
- Pregnant woman or nursing.
- Patient in emergency, people hospitalized without their assent, people without freedom, people without social health insurance.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: C
Placebo
|
26 weeks, one tablet per day
|
Active Comparator: A
Amoxicillin, Clarythromycin or metronidazole,Pantoprazole,Placebo
|
during one week for the active treatments placebo during 25 weeks
Other Names:
|
Experimental: B
Pantoprazole
|
6 months at 20 mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Measure: severity of the ulcerated gastric lesions induced by the aspirin
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To measure: percentage of patients having had at least an ulcer
Time Frame: 6 months
|
6 months
|
To measure: the average of the ranks of lesion in antrum and corpus.
Time Frame: 6 months
|
6 months
|
To measure percentage of patients having had digestive clinical events
Time Frame: 6 months
|
6 months
|
To measure: the average of the ranks of severity of the hemorrhagic lesions and erosive lesions evaluated in antrum and corpus by two analogical scales of 150 mm
Time Frame: 6 months
|
6 months
|
To measure Percentage of patients having a hemorrhagic digestive of clinical expression or detected by the biological tests.
Time Frame: 6 months
|
6 months
|
To measure : Elements of the histopathologic score of Sydney
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Dominique Lamarque, MD, PhD, Assistance Publique - Hôpitaux de Paris
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2008
Primary Completion (Actual)
March 1, 2009
Study Completion (Actual)
March 1, 2010
Study Registration Dates
First Submitted
June 18, 2008
First Submitted That Met QC Criteria
July 11, 2008
First Posted (Estimate)
July 14, 2008
Study Record Updates
Last Update Posted (Estimate)
April 21, 2015
Last Update Submitted That Met QC Criteria
April 20, 2015
Last Verified
April 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Embolism and Thrombosis
- Coronary Disease
- Thrombosis
- Coronary Thrombosis
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Gastrointestinal Agents
- Anti-Bacterial Agents
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Protein Synthesis Inhibitors
- Antiprotozoal Agents
- Antiparasitic Agents
- Anti-Ulcer Agents
- Proton Pump Inhibitors
- Metronidazole
- Amoxicillin
- Clarithromycin
- Pantoprazole
Other Study ID Numbers
- P051021
- AOM 05114
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Thrombosis
-
Prof. Stephen LeeCompletedCoronary Thrombosis | Coronary RestenosisHong Kong
-
Abbott Medical DevicesCompletedMyocardial Ischemia | Coronary Artery Disease | Coronary Disease | Coronary Occlusion | Coronary Restenosis | Vascular Disease | Coronary Artery Stenosis | Thrombosis (Stent Thrombosis)China
-
Paul S Teirstein, MDCordis CorporationCompletedCoronary Artery Disease | Coronary Thrombosis | Coronary RestenosisUnited States
-
NHS National Waiting Times Centre BoardCompletedStent Thrombosis | Coronary Stent Occlusion | Coronary Artery PerforationUnited Kingdom
-
University Hospital, CaenCompletedMyocardial Infarction | Thrombosis, CoronaryFrance
-
NHS Greater Glasgow and ClydeUnknownCoronary Stenosis | Coronary Thrombosis | Angioplasty, BalloonUnited Kingdom
-
Abbott Medical DevicesCompletedMyocardial Ischemia | Coronary Artery Disease | Coronary Arteriosclerosis | Stent Thrombosis | Vascular Disease | Coronary Artery Stenosis | Total Coronary Occlusion | Coronary Artery RestenosisItaly, Norway, Switzerland, Denmark, Spain, Poland, Belgium, Argentina, Austria, Brazil, France, Germany, Hungary, Latvia, Netherlands
-
Abbott Medical DevicesCompletedMyocardial Ischemia | Coronary Artery Disease | Coronary Arteriosclerosis | Stent Thrombosis | Vascular Disease | Coronary Artery Stenosis | Total Coronary Occlusion | Coronary Artery RestenosisFrance, Italy, Norway, China, Spain, Germany, United Kingdom, Switzerland, Israel, Denmark, Belgium, Austria, Poland, Australia, Portugal, Argentina, Brazil, Hungary, Latvia, Netherlands, India, Greece, Malaysia, Russian Federation, South... and more
-
Cliniques universitaires Saint-Luc- Université...CompletedCoronary Artery Disease | Acute Coronary Syndrome | Coronary ThrombosisBelgium
-
Scripps HealthMedtronicCompletedCoronary Artery Disease | Coronary ThrombosisUnited States
Clinical Trials on during one week for the active treatments
-
University Hospital Inselspital, BerneCompletedBreast CancerSwitzerland
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingAtopic DermatitisFrance
-
I.M. Sechenov First Moscow State Medical UniversityRecruitingKnee OsteoarthritisRussian Federation
-
University of PennsylvaniaCarnegie Mellon UniversityCompleted
-
Ain Shams UniversityCompletedCongenital Heart DiseaseEgypt
-
University of ZurichUnknownHeart Failure | Post Cardiac SurgerySwitzerland
-
Eunice Kennedy Shriver National Institute of Child...National Institute on Aging (NIA)Completed
-
Barcelonabeta Brain Research Center, Pasqual Maragall...CompletedPsychological Support to Caregivers of Azlheimer's PatientsSpain
-
Brigham and Women's HospitalRecruitingBreast Cancer | Radiology | MammographyUnited States
-
Mansoura UniversityRecruiting